Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jun 03, 2024

BUY
$2.14 - $11.62 $44,512 - $241,695
20,800 New
20,800 $234,000
Q4 2023

Jan 29, 2024

BUY
$2.14 - $11.62 $44,512 - $241,695
20,800 New
20,800 $234,000

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $349M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Vontobel Holding Ltd. Portfolio

Follow Vontobel Holding Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vontobel Holding Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Vontobel Holding Ltd. with notifications on news.